HU Intolerance or Resistance

Recognizing HU intolerance or resistance is a critical inflection point in ET management

Ongoing assessment for the first signs of hydroxyurea (HU) intolerance or resistance can help identify patients who may benefit from a change in therapy.1

John Mascarenhas, MD Professor of Medicine
“If I’m continually titrating the dose to keep neutrophils, hemoglobin, and platelets in check, I’m no longer thinking about maximizing benefit from HU. Instead, I’m beginning to consider a change in treatment strategy. It starts to beg the question: Is this still the best therapy for the patient?”
John Mascarenhas, MD Professor of Medicine, Icahn School of Medicine at Mount Sinai

The NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines®) define HU intolerance or resistance as follows1:

Platelet count >600 x 109/L
3+ months ≥2 g/d HU
(2.5 g/d in patients with a body weight >80 kg)
Platelet count >400 x 109/L
white blood cell count
<2.5 x 109/L
at any dose of HU
Platelet count >400 x 109/L
hemoglobin <10 g/dL
at any dose of HU
Presence of leg ulcers
or other unacceptable mucocutaneous manifestations at any dose of HU
HU-related fever

Clinical indicators that it may be time to change treatment

The NCCN Guidelines® identify several clinical factors that may signal the need for a change in cytoreductive therapy.1

Intolerance or Resistance
  • Intolerance or resistance to HU1
  • Intolerance or resistance to peginterferon alfa-2a or anagrelide1
Vascular Complications
  • New thrombosis, acquired von Willebrand syndrome (VWS), and/or disease-related major bleeding1
Refractory Symptoms
  • Disease-related symptoms (eg, splenomegaly, pruritus, night sweats, fatigue)1
  • Vasomotor/microvascular disturbances not responsive to aspirin (eg, headaches/chest pain, erythromelalgia)1
1 in 4 ET patients experience HU intolerance or resistance

HU intolerance or resistance is common in ET, affecting about
1 in 4 Patients2

HU intolerance or resistance marks a period of heightened risk for ET patients

HU discontinuations
27% of ET patients on HU are likely to discontinue due to toxicity and 13% are likely to discontinue due to lack of efficacy
  • 27% likely to discontinue due to toxicity3
  • 13% likely to discontinue due to lack of efficacy3
Risk of transformation

Loss of response to HU has been associated with an increased risk of transformation to myelofibrosis.4

Persistent need for dose optimization should prompt reassessment for HU resistance and ongoing disease activity.1

Controlled platelets
do not necessarily mean
controlled disease5-8

See the risks and drivers of et

BESREMi delivered
comprehensive, durable efficacy compared with anagrelide9

Explore the data

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 8, 2026. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Nejadnik B, Mascarenhas J, Rappaport LM, Lu B, Gagnon BM, Verstovsek S. Treatment of essential thrombocytopenia patients intolerant/ resistant to hydroxyurea: a physician survey. J Clin Oncol. 2017;35(15 suppl):e18565. doi:10.1200/JCO.2017.35.15_suppl.e18565 3. Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96(10):1653-1665. doi:10.1007/s00277-017-3082-y 4. Santaliestra M, Garrote M, Noya MS, et al. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia. Blood. 2024;144(suppl 1):241-242. doi:10.1182/blood-2024-198336 5. Alvarez-Larrán A, Bellosillo B, Pereira A, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol. 2014;89(5):517-523. doi:10.1002/ajh.23676 6. Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica. 2009;94(1):7-10. doi:10.3324/haematol.2008.001271 7. Kuipers RS, Kok L, Virmani R, Tefferi A. Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist. Neth Heart J. 2023;31(10):371-378. doi:10.1007/s12471-023-01757-4 8.  Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729-1737. doi:10.1182/bloodadvances.2019000211 9. BESREMi. Package insert. PharmaEssentia Corporation; 2026.

Frequently asked questions about
essential thrombocythemia (ET) and BESREMi 

Connect with us

INDICATION

BESREMi is indicated for the treatment of adults with essential thrombocythemia.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DISORDERS

Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy.

CONTRAINDICATIONS

  • Existence of or history of severe depression, suicidal ideation, or suicide attempt
  • Hypersensitivity to interferons or any inactive ingredients
  • Moderate or severe hepatic impairment
  • History or presence of active serious or untreated autoimmune disease
  • Immunosuppressed transplant recipients

WARNINGS AND PRECAUTIONS

  • Depression and Suicide: Closely monitor patients for any symptoms of psychiatric disorders and, if needed, consider psychiatric consultation and treatment or dosage modifications as listed in the full prescribing information.
  • Endocrine Toxicity: Do not use BESREMi in patients with active serious or untreated endocrine disorders associated with autoimmune disease. Evaluate thyroid function in patients who develop symptoms suggestive of thyroid disease during BESREMi therapy. Discontinue BESREMi in patients who develop endocrine disorders that cannot be adequately managed during treatment with BESREMi.
  • Cardiovascular Toxicity: Patients with a history of cardiovascular disorders should be closely monitored for cardiovascular toxicity during BESREMi therapy. Avoid use of BESREMi in patients with severe or unstable cardiovascular disease or recent stroke or myocardial infarction.
  • Decreased Peripheral Blood Counts: Monitor complete blood counts at baseline, during titration, and every 3-6 months during the maintenance phase.
  • Pancreatitis/Colitis/Pulmonary Toxicity: Interrupt BESREMi treatment in patients with possible pancreatitis, colitis, or pulmonary toxicity and evaluate promptly. Consider discontinuation of BESREMi in patients with confirmed pancreatitis or who show signs or symptoms of serious ulcerative or hemorrhagic colitis, or who develop pulmonary infiltrates or pulmonary function impairment.
  • Ophthalmologic Toxicity: Advise patients to have eye examinations before and during treatment. Discontinue BESREMi in patients who develop new or worsening eye disorders.
  • Hyperlipidemia/Hepatotoxicity/Renal Toxicity: Monitor serum triglycerides, liver enzymes, hepatic function, and serum creatinine at baseline and during therapy. Avoid use of BESREMi in patients with eGFR <30 mL/min. Discontinue BESREMi in patients with persistently marked elevated triglycerides, evidence of hepatic decompensation, or if renal impairment develops during treatment.
  • Dental and Periodontal Toxicity: Patients should have good oral hygiene and regular dental examinations.
  • Dermatologic Toxicity: Consider discontinuation of BESREMi if clinically significant dermatologic toxicity occurs.
  • Driving and Operating Machinery: BESREMi may impact the ability to drive and use machinery. Patients should not drive or use heavy machinery until they know how BESREMi affects their abilities. Patients who experience dizziness, somnolence, or hallucination during BESREMi therapy should avoid driving or using machinery.
  • Embryo-Fetal Toxicity: Based on the mechanism of action, BESREMi can cause fetal harm when administered to a pregnant woman. Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with BESREMi. Advise females of reproductive potential to use an effective method of contraception during treatment with BESREMi and for at least 8 weeks after the final dose. Advise women not to breastfeed during treatment and for 8 weeks after the final dose.

ADVERSE REACTIONS

The most common adverse reactions reported in >30% of patients were aspartate aminotransferase increased (44%), alanine aminotransferase increased (43%), and fatigue (31%).

DRUG INTERACTIONS

Patients on BESREMi who are receiving concomitant drugs which are CYP450 substrates with a narrow therapeutic index should be monitored to inform the need for dosage modification. Avoid use with myelosuppressive agents, narcotics, hypnotics, or sedatives, and monitor patients receiving the combination for effects of excessive CNS toxicity.
To report SUSPECTED ADVERSE REACTIONS, contact PharmaEssentia at 1-800-999-2449 or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.
Please see full Prescribing Information, including Boxed Warning.